<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIOVAN
                         - valsartan tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold"> Diovan</span> <span class="Bold">safely and effectively. </span><span class="Bold">See full prescribing information for</span><span class="Bold"> Diovan.</span><br><span class="Bold">Diovan (valsartan) Tablets</span><br><span class="Bold">Initial U.S. Approval:</span><span class="Bold">  1996</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING:</span><span class="Bold">  USE IN PREGNANCY</span>
</h1>
<h1 class="Warning">
<span class="Bold">When pregnancy</span><span class="Bold"> is detected, discontinue Diovan as soon as possible. D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus</span> <span class="Bold">(5.1)</span><span class="Bold"> </span>
</h1>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING:</span><span class="Bold">  USE IN PREGNANCY</span>
</h1>
<h1 class="Warning">
<span class="Bold">When pregnancy</span><span class="Bold"> is detected, discontinue Diovan as soon as possible. D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus</span> <span class="Bold">(5.1)</span><span class="Bold"> </span>
</h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Diovan is an angiotensin II receptor blocker (ARB) indicated for:  (<a href="#section-1">1</a>)</p>
<ul class="Disc">
<li>Treatment of <span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></span> (1.1)<br>
</li>
<li>Treatment of <span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></span> (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2)<br>
</li>
<li>Reduction of cardiovascular mortality in clinically stable patients with <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span> or <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> <span class="Bold">following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></span> (1.3)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="i63af0317-a4e3-4fda-8e3d-b88d7b290c03"></a><table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Indication</span></td>
<td class="Lrule Rrule Toprule" align="left">
<span class="Bold">Starting </span><span class="Bold">D</span><span class="Bold">ose</span>
</td>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Dose Range</span></td>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Target Maintenance Dose*</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Adult <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (2.1)</td>
<td class="Lrule Rrule Toprule" align="left">80 or 160 mg once daily</td>
<td class="Lrule Rrule Toprule" align="left">80-320 mg once daily</td>
<td class="Lrule Rrule Toprule" align="left">---</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Pediatric <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (6-16 years) (2.1)</td>
<td class="Lrule Rrule Toprule" align="left">1.3 mg/kg once daily (up to 40 mg total)</td>
<td class="Lrule Rrule Toprule" align="left">1.3-2.7 mg/kg once daily (up to 40-160 mg total)</td>
<td class="Lrule Rrule Toprule" align="left">---</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> (2.2)</td>
<td class="Lrule Rrule Toprule" align="left">40 mg twice daily</td>
<td class="Lrule Rrule Toprule" align="left">40-160 mg twice daily</td>
<td class="Lrule Rrule Toprule" align="left">160 mg twice daily</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left">Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> (2.3)</td>
<td class="Lrule Rrule Toprule" align="left">20 mg twice daily</td>
<td class="Lrule Rrule Toprule" align="left">20-160 mg twice daily</td>
<td class="Lrule Rrule Toprule" align="left">160 mg twice daily</td>
</tr>
</tbody>
</table>
<p class="Highlighta">* as tolerated by patient  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">No initial dosage adjustment is required for elderly patients, for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or for patients with mild or moderate liver insufficiency. Care should be exercised with dosing of Diovan in patients with hepatic or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Diovan may be administered with or without food. In <span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> </span>patients, consideration should be given to reducing the dose of concomitant diuretics. <span class="Bold">Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></span>, consideration should be given to a dosage reduction if symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or renal dysfunction occurs.  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets (mg):  40 (scored), 80, 160, 320  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid fetal or neonatal exposure (5.1)<br>
</li>
<li>Observe for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (5.2)<br>
</li>
<li>Use with caution in patients with impaired hepatic (5.3) or renal (5.4) function</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:</span>  Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>:</span>  Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span>  Most common adverse reactions which caused patients to discontinue therapy are <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and increased blood creatinine (6.1)   (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Potassium sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, increases in serum creatinine (7)<br>
</li>
<li>NSAIDS use may lead to increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and loss of anti-hypertensive effect (7)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Nursing Mothers:</span>  Nursing or drug should be discontinued (8.3); <span class="Bold">Pediatrics</span>:  Efficacy and safety data support use in 6-16 year old patients (8.4); <span class="Bold">Geriatrics</span>:  No overall difference in efficacy or safety vs. younger patients, but greater sensitivity of some older individuals cannot be ruled out (8.5)   (<a href="#section-8">8</a>)</p>
<p class="Highlighta">
		     
	  (<a href="#section-8">8</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">USE IN PREGNANCY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span><span class="Bold">  </span><span class="Bold">INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="Bold">1.3 Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold">  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1</span><span class="Bold"> </span><span class="Bold">Adult </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 </span><span class="Bold">Pediatric Hypertensi</span><span class="Bold">on</span><span class="Bold"> </span><span class="Bold">6-16</span><span class="Bold"> year</span><span class="Bold">s</span><span class="Bold"> of age</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.</span><span class="Bold">3</span><span class="Bold"> </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.</span><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span><span class="Bold">  </span><span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span><span class="Bold">  </span><span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Impaired Hepatic Function</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span><span class="Bold">  </span><span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 </span><span class="Bold">Clinical Studies Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Post-Marketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 </span><span class="Bold">Clinical </span><span class="Bold">Laboratory Test </span><span class="Bold">Findings</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 </span><span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4 </span><span class="Bold">Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold">  </span><span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span><span class="Bold">  </span><span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.2 Animal Toxicology and/or Pharmacology</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span><span class="Bold">  </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></a></h2>
<h2><a href="#section-13.3" class="toc"><span class="Bold">14.3</span><span class="Bold"> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span><span class="Bold">  </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17</span><span class="Bold">  </span><span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">USE IN PREGNANCY</span>
</h1>
<p class="First"><span class="Bold">When used in pregnancy, drugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span><span class="Bold"> </span><span class="Bold">When pregnancy is detected, Diovan should be discontinued as soon as possible.</span></p>
<p><span class="Bold">See WARNINGS:</span><span class="Bold"> </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span><span class="Bold"> (5.1)</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold">  </span><span class="Bold">INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First">Diovan<span class="Sup">®</span> (valsartan) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with other antihypertensive agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></h2>
<p class="First">Diovan is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (NYHA class II-IV). In a controlled clinical trial, Diovan significantly reduced hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. There is no evidence that Diovan provides added benefits when it is used with an adequate dose of an ACE inhibitor. <span class="Italics">[</span><span class="Italics">See </span><span class="Italics">Clinical Studies</span><span class="Italics"> (14.2)]</span><span class="Italics"> </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.3"></a><p></p>
<h2><span class="Bold">1.3 Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></h2>
<p class="First">In clinically stable patients with <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span> or <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, Diovan is indicated to reduce cardiovascular mortality. <span class="Italics">[</span><span class="Italics">See </span><span class="Italics">Clinical Studies</span><span class="Italics"> (14.3</span><span class="Italics">)</span><span class="Italics">]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span><span class="Bold"> </span><span class="Bold">Adult </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First">The recommended starting dose of Diovan (valsartan) is 80 mg or 160 mg once daily when used as monotherapy in patients who are not volume-depleted. Patients requiring greater reductions may be started at the higher dose. Diovan may be used over a dose range of 80 mg to 320 mg daily, administered once a day.</p>
<p>The antihypertensive effect is substantially present within 2 weeks and maximal reduction is generally attained after 4 weeks. If additional antihypertensive effect is required over the starting dose range, the dose may be increased to a maximum of 320 mg or a diuretic may be added. Addition of a diuretic has a greater effect than dose increases beyond 80 mg. </p>
<p>No initial dosage adjustment is required for elderly patients, for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or for patients with mild or moderate liver insufficiency. Care should be exercised with dosing of Diovan in patients with hepatic or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p>Diovan may be administered with other antihypertensive agents. </p>
<p>Diovan may be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.2 </span><span class="Bold">Pediatric Hypertensi</span><span class="Bold">on</span><span class="Bold"> </span><span class="Bold">6-16</span><span class="Bold"> year</span><span class="Bold">s</span><span class="Bold"> of age</span>
</h2>
<p class="First">For children who can swallow tablets, the usual recommended starting dose is 1.3 mg/kg once daily (up to 40 mg total). The dosage should be adjusted according to blood pressure response. Doses higher than 2.7 mg/kg (up to 160 mg) once daily have not been studied in pediatric patients 6 to 16 years old. </p>
<p>For children who cannot swallow tablets, or children for whom the calculated dosage (mg/kg) does not correspond to the available tablet strengths of Diovan, the use of a suspension is recommended. Follow the suspension preparation instructions below (see <span class="Bold">Preparation of Suspension</span>) to administer valsartan as a suspension. When the suspension is replaced by a tablet, the dose of valsartan may have to be increased. The exposure to valsartan with the suspension is 1.6 times greater than with the tablet.</p>
<p>Diovan is not recommended for treatment of children below the age of 6 years or children of any age with a glomerular filtration rate &lt;30 mL/min/1.73 m<span class="Sup">2</span>, as no data are available. </p>
<p><span class="Bold">Preparation of Suspension (for </span><span class="Bold">160 mL of a 4 </span><span class="Bold">mg/mL suspension)</span></p>
<p>Add 80 mL of Ora-Plus<span class="Sup">®</span>* oral suspending vehicle to an amber glass bottle containing 8 Diovan 80 mg tablets, and shake for a minimum of 2 minutes. Allow the suspension to stand for a minimum of 1 hour. After the standing time, shake the suspension for a minimum of 1 additional minute. Add 80 mL of Ora-Sweet SF<span class="Sup">®</span>* oral sweetening vehicle to the bottle and shake the suspension for at least 10 seconds to disperse the ingredients. The suspension is homogenous and can be stored for either up to 30 days at room temperature (below 30ºC/86ºF) or up to 75 days at refrigerated conditions (2-8ºC/35-46ºF) in the glass bottle with a child-resistant screw-cap closure. Shake the bottle well (at least 10 seconds) prior to dispensing the suspension.</p>
<p>*Ora-Sweet SF<span class="Sup">®</span> and Ora-Plus<span class="Sup">®</span> are registered trademarks of Paddock Laboratories, Inc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">3</span><span class="Bold"> </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span>
</h2>
<p class="First">The recommended starting dose of Diovan is 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily should be done to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span>
</h2>
<p class="First">Diovan may be initiated as early as 12 hours after a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. The recommended starting dose of Diovan is 20 mg twice daily. Patients may be uptitrated within 7 days to 40 mg twice daily, with subsequent titrations to a target maintenance dose of 160 mg twice daily, as tolerated by the patient. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or renal dysfunction occurs, consideration should be given to a dosage reduction. Diovan may be given with other standard post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> treatment, including thrombolytics, aspirin, beta-blockers, and statins. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">40 mg are scored yellow ovaloid tablets with beveled edges, imprinted NVR/DO (Side 1/Side 2)</p>
<p>80 mg are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> red almond-shaped tablets with beveled edges, imprinted NVR/DV</p>
<p>160 mg are grey-orange almond-shaped tablets with beveled edges, imprinted NVR/DX</p>
<p>320 mg are dark grey-violet almond-shaped tablets with beveled edges, imprinted NVR/DXL</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span><span class="Bold">  </span><span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">None </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span><span class="Bold">  </span><span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span>
</h2>
<p class="First">Diovan can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus<span class="Italics">. </span></p>
<p>Drugs that act on the renin angiotensin system can cause fetal and neonatal morbidity and mortality when used in pregnancy. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Italics">[See Use in Specific Populations (8.1)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></h2>
<p class="First">Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was rarely seen (0.1%) in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with Diovan alone. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur. This condition should be corrected prior to administration of Diovan, or the treatment should start under close medical supervision.</p>
<p>Caution should be observed when initiating therapy in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients. Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients given Diovan commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually is not necessary when dosing instructions are followed. In controlled trials in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, the incidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in valsartan-treated patients was 5.5% compared to 1.8% in placebo-treated patients. In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients. </p>
<p>If excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Impaired Hepatic Function</span></h2>
<p class="First">As the majority of valsartan is eliminated in the bile, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, including patients with biliary obstructive disorders, showed lower valsartan clearance (higher AUCs). Care should be exercised in administering Diovan to these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></h2>
<p class="First">In studies of ACE inhibitors in hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen have been reported. In a 4-day trial of valsartan in 12 hypertensive patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">unilateral renal artery stenosis</span>, no significant increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of Diovan in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but an effect similar to that seen with ACE inhibitors should be anticipated.</p>
<p>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar outcomes have been reported with Diovan.</p>
<p>Some patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have developed increases in blood urea nitrogen, serum creatinine, and potassium. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of the diuretic and/or Diovan may be required. In the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, in which 93% of patients were on concomitant ACE inhibitors, treatment was discontinued for elevations in creatinine or potassium (total of 1.0% on valsartan vs. 0.2% on placebo). In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients and 0.8% of captopril-treated patients. Evaluation of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> should always include assessment of renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span><span class="Bold">  </span><span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1 </span><span class="Bold">Clinical Studies Experience</span>
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Adult </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>Diovan (valsartan) has been evaluated for safety in more than 4,000 patients, including over 400 treated for over 6 months, and more than 160 for over 1 year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse reactions with Diovan was similar to placebo.</p>
<p>The overall frequency of adverse reactions was neither dose-related nor related to gender, age, race, or regimen. Discontinuation of therapy due to side effects was required in 2.3% of valsartan patients and 2.0% of placebo patients. The most common reasons for discontinuation of therapy with Diovan were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>The adverse reactions that occurred in placebo-controlled clinical trials in at least 1% of patients treated with Diovan and at a higher incidence in valsartan (n=2,316) than placebo (n=888) patients included <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> (3% vs. 2%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (2% vs. 1%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2% vs. 1%). </p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> occurred at a more than 1% rate but at about the same incidence in placebo and valsartan patients.</p>
<p>In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> was significantly greater in the ACE-inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had had <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> when they had previously received ACE inhibitors, the incidences of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in patients who received valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively (p &lt;0.001).</p>
<p>Dose-related orthostatic effects were seen in less than 1% of patients. An increase in the incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in patients treated with Diovan 320 mg (8%) compared to 10 to 160 mg (2% to 4%). </p>
<p>Diovan has been used concomitantly with hydrochlorothiazide without evidence of clinically important adverse interactions.</p>
<p>Other adverse reactions that occurred in controlled clinical trials of patients treated with Diovan (&gt;0.2% of valsartan patients) are listed below. It cannot be determined whether these events were causally related to Diovan.</p>
<p><span class="Bold Italics">Body as a Whole</span><span class="Italics">:</span>  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p>
<p><span class="Bold Italics">Cardiovascular:</span>  <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p>
<p><span class="Bold Italics">Dermatologic:</span>  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold Italics">Digestive:</span>  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span></p>
<p><span class="Bold Italics">Musculoskeletal:</span>  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Bold Italics">Neurologic and Psychiatric:</span>  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold Italics">Respiratory:</span>  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
<p><span class="Bold Italics">Special Senses:</span>  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p>
<p><span class="Bold Italics">Urogenital:</span>  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></p>
<p>Other reported events seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Pediatric Hypertensi</span><span class="Bold">on</span></p>
<p>No relevant differences were identified between the adverse experience profile for pediatric patients aged 6-16 years and that previously reported for adult patients. Neurocognitive and developmental assessment of pediatric patients aged 6 to 16 years revealed no overall clinically relevant adverse impact after treatment with Diovan for up to one year.</p>
<p>In the one study (n=90) of pediatric patients (1-5 years), two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and three cases of on-treatment transaminase elevations were seen in the one-year open-label extension phase. These 5 events occurred in a study population in which patients frequently had significant co-morbidities. A causal relationship to Diovan has not been established. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></p>
<p>The adverse experience profile of Diovan in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients was consistent with the pharmacology of the drug and the health status of the patients. In the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, comparing valsartan in total daily doses up to 320 mg (n=2,506) to placebo (n=2,494), 10% of valsartan patients discontinued for adverse reactions vs. 7% of placebo patients. </p>
<p>The table shows adverse reactions in double-blind short-term <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> trials, including the first 4 months of the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, with an incidence of at least 2% that were more frequent in valsartan-treated patients than in placebo-treated patients. All patients received standard drug therapy for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, frequently as multiple medications, which could include diuretics, digitalis, beta-blockers, or ACE inhibitors. </p>
<a name="i68e2cae4-dfec-4903-844e-89579611aacb"></a><table>
<col width="215">
<col width="198">
<col width="207">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule">Valsartan (n=3,282)</td>
<td class="Toprule">Placebo (n=2,740)</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Toprule">17%</td>
<td class="Toprule">9%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Toprule">7%</td>
<td class="Toprule">2%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Toprule">5%</td>
<td class="Toprule">4%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Toprule">3%</td>
<td class="Toprule">2%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Toprule">3%</td>
<td class="Toprule">2%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Toprule">3%</td>
<td class="Toprule">2%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, postural</td>
<td class="Toprule">2%</td>
<td class="Toprule">1%</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></td>
<td class="Toprule">2%</td>
<td class="Toprule">1%</td>
</tr>
<tr class="Last">
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, postural</td>
<td class="Toprule">2%</td>
<td class="Toprule">1%</td>
</tr>
</tbody>
</table>
<p>Other adverse reactions with an incidence greater than 1% and greater than placebo included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> NOS, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> NOS, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. (NOS = not otherwise specified).</p>
<p>From the long-term data in the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, there did not appear to be any significant adverse reactions not previously identified.</p>
<p><span class="Bold">Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></p>
<p>The safety profile of Diovan was consistent with the pharmacology of the drug and the background diseases, cardiovascular risk factors, and clinical course of patients treated in the post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> setting. The table shows the percent of patients discontinued in the valsartan and captopril-treated groups in the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT) with a rate of at least 0.5% in either of the treatment groups.</p>
<a name="ic584beaa-8b5d-47df-8539-8f9dfbcb166b"></a><table>
<col width="247">
<col width="180">
<col width="192">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule">Valsartan (n=4,885)</td>
<td class="Toprule">Captopril (n=4,879)</td>
</tr>
<tr>
<td class="Toprule">Discontinuation for adverse reaction</td>
<td class="Toprule">5.8%</td>
<td class="Toprule">7.7%</td>
</tr>
<tr>
<td class="Toprule">Adverse reactions</td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td class="Toprule">
		     
	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> NOS</td>
<td class="Toprule">1.4%</td>
<td class="Toprule">0.8%</td>
</tr>
<tr>
<td class="Toprule">
		     
	<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Toprule">0.6%</td>
<td class="Toprule">2.5%</td>
</tr>
<tr>
<td class="Toprule">
		     
	Blood creatinine increased</td>
<td class="Toprule">0.6%</td>
<td class="Toprule">0.4%</td>
</tr>
<tr class="Last">
<td class="Toprule">
		     
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> NOS</td>
<td class="Toprule">0.2%</td>
<td class="Toprule">0.6%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Post-Marketing Experience</span></h2>
<p class="First">The following additional adverse reactions have been reported in post-marketing experience:</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span>  There are rare reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; </p>
<p><span class="Bold Italics">Digestive:</span>  Elevated liver enzymes and very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>;</p>
<p><span class="Bold Italics">Renal:</span>  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span>;</p>
<p><span class="Bold Italics">Clinical Laboratory Tests:</span>  <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>;</p>
<p><span class="Bold Italics">Dermatologic:</span>  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>.</p>
<p><span class="Bold Italics">Blood and Lymphatic:</span>  There are very rare reports of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold Italics">Vascular:</span>  <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>.</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers.</p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DRUG INTERACTIONS</span>
</h1>
<p class="First">No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when Diovan (valsartan) was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.</p>
<p>Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.</p>
<p><span class="Italics">CYP 450 Interactions:</span> The enzyme(s) responsible for valsartan metabolism have not been identified but do not seem to be CYP 450 isozymes. The inhibitory or induction potential of valsartan on CYP 450 is also unknown.</p>
<p><span class="Italics">Transporters:</span><span class="Italics"> </span>The results from an <span class="Italics">in vitro</span> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan. </p>
<p>As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients to increases in serum creatinine.</p>
<p><span class="Italics">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):  </span>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  These effects are usually reversible.  Monitor renal function periodically in patients receiving valsartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including valsartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">7.1 </span><span class="Bold">Clinical </span><span class="Bold">Laboratory Test </span><span class="Bold">Findings</span>
</h2>
<p class="First">In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Diovan.</p>
<p><span class="Bold Italics">Creatinine:</span><span class="Bold Italics"> </span> Minor elevations in creatinine occurred in 0.8% of patients taking Diovan and 0.6% given placebo in controlled clinical trials of hypertensive patients. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> trials, greater than 50% increases in creatinine were observed in 3.9% of Diovan-treated patients compared to 0.9% of placebo-treated patients. In post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients and 3.4% of captopril-treated patients. </p>
<p><span class="Bold Italics">Hemoglobin and Hematocrit:</span>  Greater than 20% decreases in hemoglobin and hematocrit were observed in 0.4% and 0.8%, respectively, of Diovan patients, compared with 0.1% and 0.1% in placebo-treated patients. One valsartan patient discontinued treatment for <span class="product-label-link" type="condition" conceptid="4121106" conceptname="Microcytic anemia">microcytic anemia</span>.</p>
<p><span class="Bold Italics">Liver Function Tests:</span>  Occasional elevations (greater than 150%) of liver chemistries occurred in Diovan-treated patients. Three patients (&lt; 0.1%) treated with valsartan discontinued treatment for elevated liver chemistries.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>:</span>  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was observed in 1.9% of patients treated with Diovan and 0.8% of patients treated with placebo.</p>
<p><span class="Bold Italics">Serum Potassium:</span>  In hypertensive patients, greater than 20% increases in serum potassium were observed in 4.4% of Diovan-treated patients compared to 2.9% of placebo-treated patients. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 20% increases in serum potassium were observed in 10.0% of Diovan-treated patients compared to 5.1% of placebo-treated patients.</p>
<p><span class="Bold Italics">Blood Urea Nitrogen (BUN):</span>  In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> trials, greater than 50% increases in BUN were observed in 16.6% of Diovan-treated patients compared to 6.3% of placebo-treated patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1 </span><span class="Bold">Pregnancy</span>
</h2>
<p class="First">Teratogenic Effects:  Pregnancy Category D </p>
<p>Diovan, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when used during the second or third trimester of pregnancy. Diovan can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. </p>
<p>Angiotensin II receptor antagonists, like valsartan, and angiotensin converting enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin system. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> was also reported, presumably from decreased fetal renal function. In this setting, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> was associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> were also reported, although it is not clear whether these occurrences were due to exposure to the drug. In a retrospective study, first trimester use of ACE inhibitors, a specific class of drugs acting on the renin angiotensin system, was associated with a potential risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</p>
<p>When pregnancy occurs in a patient using Diovan, the physician should discontinue Diovan treatment as soon as possible. The physician should inform the patient about potential risks to the fetus based on the time of gestational exposure to Diovan (first trimester only or later). If exposure occurs beyond the first trimester, an ultrasound examination should be done. </p>
<p>In rare cases when another antihypertensive agent can not be used to treat the pregnant patient, serial ultrasound examinations should be performed to assess the intraamniotic environment. Routine fetal testing with non-stress tests, biophysical profiles, and/or contraction stress tests may be appropriate based on gestational age and standards of care in the community. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> occurs in these situations, individualized decisions about continuing or discontinuing Diovan treatment and about pregnancy management should be made by the patient, her physician, and experts in the management of high risk pregnancy. Patients and physicians should be aware that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of in utero exposure to Diovan should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, these infants may require blood pressure and renal perfusion support. Exchange transfusion or dialysis may be required to reverse <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or support decreased renal function.</p>
<p>Healthcare professionals who prescribe drugs acting directly on the renin angiotensin system should counsel women of childbearing potential about the risks of these agents during pregnancy. <span class="Italics">[See Nonclincial Toxicology (13.2)]</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span>
</h2>
<p class="First">It is not known whether Diovan is excreted in human milk. Diovan was excreted in the milk of lactating rats; however, animal breast milk drug levels may not accurately reflect human breast milk levels. Because many drugs are excreted into human milk and because of the potential for adverse reactions in nursing infants from Diovan, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.4 </span><span class="Bold">Pediatric Use</span>
</h2>
<p class="First">The antihypertensive effects of Diovan have been evaluated in two randomized, double-blind clinical studies in pediatric patients from 1-5 and 6-16 years of age <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Clinical Studies</span><span class="Italics">(14.1</span><span class="Italics">)]</span>. The pharmacokinetics of Diovan have been evaluated in pediatric patients 1 to 16 years of age <span class="Italics">[</span><span class="Italics">see Pharmacokinetics, </span><span class="Italics">Special Populations, Pediatric </span><span class="Italics">(12.3)</span><span class="Italics">]</span>. Diovan was generally well tolerated in children 6-16 years and the adverse experience profile was similar to that described for adults. Diovan is not recommended for pediatric patients under 6 years of age due to safety findings for which a relationship to treatment could not be excluded <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Adverse Reactions</span><span class="Italics">, Pediatric <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (6.1)</span><span class="Italics">]</span>.</p>
<p>Daily oral dosing of neonatal/juvenile rats with valsartan at doses as low as 1 mg/kg/day (about 10% of the maximum recommended pediatric dose on a mg/m<span class="Sup">2</span> basis) from postnatal day 7 to postnatal day 70 produced persistent, irreversible kidney damage. These kidney effects in neonatal rats represent expected exaggerated pharmacological effects that are observed if rats are treated during the first 13 days of life. Since this period coincides with up to 44 weeks after conception in humans, it is not considered to point toward an increased safety concern in 6 to 16 year old children. </p>
<p>Diovan is not recommended for treatment of children with glomerular filtration rates &lt;30 mL/min/1.73 m<span class="Sup">2</span>, as no data are available. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span>
</h2>
<p class="First">In the controlled clinical trials of valsartan, 1,214 (36.2%) of hypertensive patients treated with valsartan were ≥65 years and 265 (7.9%) were ≥75 years. No overall difference in the efficacy or safety of valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out. </p>
<p>Of the 2,511 patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> randomized to valsartan in the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, 45% (1,141) were 65 years of age or older. In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), 53% (2,596) of the 4,909 patients treated with valsartan and 51% (2,515) of the 4,885 patients treated with valsartan + captopril were 65 years of age or older. There were no notable differences in efficacy or safety between older and younger patients in either trial.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold">  </span><span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First">Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted. </p>
<p>Diovan (valsartan) is not removed from the plasma by hemodialysis.</p>
<p>Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the rat and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the marmoset at the highest dose (60 and 31 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold">  </span><span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">Diovan (valsartan) is a nonpeptide, orally active, and specific angiotensin II receptor blocker acting on the AT<span class="Sub">1</span> receptor subtype.</p>
<p>Valsartan is chemically described as <span class="Italics">N</span>-(1-oxopentyl)-<span class="Italics">N</span>-[[2′-(1<span class="Italics">H</span>-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl]-L-valine. Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">29</span>N<span class="Sub">5</span>O<span class="Sub">3</span>, its molecular weight is 435.5, and its structural formula is</p>
<p>
		     
	<img alt="Valsartan structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e4382de-df78-4821-b11e-c423442a7ff8&amp;name=diovan-tablets-01.jpg"></p>
<p>Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water.</p>
<p>Diovan is available as tablets for oral administration, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides (yellow, black and/or red), magnesium stearate, microcrystalline cellulose, polyethylene glycol 8000, and titanium dioxide. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span>
</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Diovan (valsartan) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. </p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. The increased plasma levels of angiotensin II following AT<span class="Sub">1</span> receptor blockade with valsartan may stimulate the unblocked AT<span class="Sub">2</span> receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT<span class="Sub">1</span> receptor about one-200th that of valsartan itself.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span>
</h2>
<p class="First">Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. No information on the effect of larger doses is available. </p>
<p>Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed. </p>
<p>In multiple-dose studies in hypertensive patients with stable <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>, valsartan had no clinically significant effects on glomerular filtration rate, filtration fraction, creatinine clearance, or renal plasma flow. </p>
<p>In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, fasting triglycerides, fasting serum glucose, or uric acid. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span>
</h2>
<p class="First">Valsartan peak plasma concentration is reached 2 to 4 hours after dosing. Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. Absolute bioavailability for Diovan is about 25% (range 10%-35%).<span class="Bold Italics"> </span>The bioavailability of the suspension (see [2.2] Dosage and Administration; Pediatric <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>) is 1.6 times greater than with the tablet. With the tablet, food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<span class="Sub">max</span>) by about 50%. AUC and C<span class="Sub">max</span> values of valsartan increase approximately linearly with increasing dose over the clinical dosing range. Valsartan does not accumulate appreciably in plasma following repeated administration.</p>
<p><span class="Bold">Metabolism and Elimination:</span>  Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites. The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan. The enzyme(s) responsible for valsartan metabolism have not been identified but do not seem to be CYP 450 isozymes.</p>
<p>Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30% of total clearance).</p>
<p><span class="Bold">Distribution:</span>  The steady state volume of distribution of valsartan after intravenous administration is small (17 L), indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin.</p>
<p><span class="Bold Italics">Special Populations:</span></p>
<p><span class="Bold Italics">Pediatric:</span>  In a study of pediatric hypertensive patients (n=26, 1-16 years of age) given single doses of a suspension of Diovan (mean:  0.9 to 2 mg/kg), the clearance (L/h/kg) of valsartan for children was similar to that of adults<span class="Bold Italics"> </span>receiving the same formulation. </p>
<p><span class="Bold Italics">Geriatric:</span>  Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. No dosage adjustment is necessary <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Dosage and Administration</span><span class="Italics"> (2.1</span><span class="Italics">)]</span>.</p>
<p><span class="Bold Italics">Gender:</span>  Pharmacokinetics of valsartan does not differ significantly between males and females.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>:</span>  The average time to peak concentration and elimination half-life of valsartan in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients are similar to that observed in healthy volunteers. AUC and C<span class="Sub">max</span> values of valsartan increase linearly and are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 L/h. Age does not affect the apparent clearance in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span>  There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Consequently, dose adjustment is not required in patients with mild-to-moderate renal dysfunction. No studies have been performed in patients with severe impairment of renal function (creatinine clearance &lt;10 mL/min). Valsartan is not removed from the plasma by hemodialysis. In the case of severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, exercise care with dosing of valsartan <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Dosage and Administration </span><span class="Italics">(2.1</span><span class="Italics">)].</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span>  On average, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex and weight). In general, no dosage adjustment is needed in patients with mild-to-moderate liver disease. Care should be exercised in patients with liver disease <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Dosage and Administration</span><span class="Italics"> (2.1)</span><span class="Italics">]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First">There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2 years at doses up to 160 and 200 mg/kg/day, respectively. These doses in mice and rats are about 2.6 and 6 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p>Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> (Ames) and <span class="Italics">E coli</span>; a gene mutation test with Chinese hamster V79 cells; a cytogenetic test with Chinese hamster ovary cells; and a rat micronucleus test. </p>
<p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12.2"></a><p></p>
<h2><span class="Bold">13.2 Animal Toxicology and/or Pharmacology</span></h2>
<p class="First"><span class="Bold">Reproductive Toxicology Studies</span></p>
<p>No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200 and 2 mg/kg/day in mice, rats and rabbits represent 9, 6, and 0.1 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. Calculations assume an oral dose of 320 mg/day and a 60-kg patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold">  </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">14.1 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First"><span class="Bold">Adult </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>The antihypertensive effects of Diovan (valsartan) were demonstrated principally in 7 placebo-controlled, 4- to 12-week trials (one in patients over 65) of dosages from 10 to 320 mg/day in patients with baseline diastolic blood pressures of 95-115. The studies allowed comparison of once-daily and twice-daily regimens of 160 mg/day; comparison of peak and trough effects; comparison (in pooled data) of response by gender, age, and race; and evaluation of incremental effects of hydrochlorothiazide.</p>
<p>Administration of valsartan to patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> results in a significant reduction of sitting, supine, and standing systolic and diastolic blood pressure, usually with little or no orthostatic change.</p>
<p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs at approximately 2 hours, and maximum reduction of blood pressure is achieved within 6 hours. The antihypertensive effect persists for 24 hours after dosing, but there is a decrease from peak effect at lower doses (40 mg) presumably reflecting loss of inhibition of angiotensin II. At higher doses, however (160 mg), there is little difference in peak and trough effect. During repeated dosing, the reduction in blood pressure with any dose is substantially present within 2 weeks, and maximal reduction is generally attained after 4 weeks. In long-term follow-up studies (without placebo control), the effect of valsartan appeared to be maintained for up to two years. The antihypertensive effect is independent of age, gender or race. The latter finding regarding race is based on pooled data and should be viewed with caution, because antihypertensive drugs that affect the renin-angiotensin system (that is, ACE inhibitors and angiotensin-II blockers) have generally been found to be less effective in low-renin hypertensives (frequently blacks) than in high-renin hypertensives (frequently whites). In pooled, randomized, controlled trials of Diovan that included a total of 140 blacks and 830 whites, valsartan and an ACE-inhibitor control were generally at least as effective in blacks as whites. The explanation for this difference from previous findings is unclear.</p>
<p>Abrupt withdrawal of valsartan has not been associated with a rapid increase in blood pressure.</p>
<p>The blood pressure lowering effect of valsartan and thiazide-type diuretics are approximately additive.</p>
<p>The 7 studies of valsartan monotherapy included over 2,000 patients randomized to various doses of valsartan and about 800 patients randomized to placebo. Doses below 80 mg were not consistently distinguished from those of placebo at trough, but doses of 80, 160 and 320 mg produced dose-related decreases in systolic and diastolic blood pressure, with the difference from placebo of approximately 6-9/3-5 mmHg at 80-160 mg and 9/6 mmHg at 320 mg. In a controlled trial the addition of HCTZ to valsartan 80 mg resulted in additional lowering of systolic and diastolic blood pressure by approximately 6/3 and 12/5 mmHg for 12.5 and 25 mg of HCTZ, respectively, compared to valsartan 80 mg alone.</p>
<p>Patients with an inadequate response to 80 mg once daily were titrated to either 160 mg once daily or 80 mg twice daily, which resulted in a comparable response in both groups. </p>
<p>In controlled trials, the antihypertensive effect of once-daily valsartan 80 mg was similar to that of once-daily enalapril 20 mg or once-daily lisinopril 10 mg.</p>
<p>There was essentially no change in heart rate in valsartan-treated patients in controlled trials.</p>
<p><span class="Bold">Pediatric Hypertensi</span><span class="Bold">on</span><span class="Bold"> </span></p>
<p>The antihypertensive effects of Diovan were evaluated in two randomized, double-blind clinical studies.</p>
<p>In a clinical study involving 261 hypertensive pediatric patients 6 to 16 years of age, patients who weighed &lt; 35 kg received 10, 40 or 80 mg of valsartan daily (low, medium and high doses), and patients who weighed ≥ 35 kg received 20, 80, and 160 mg of valsartan daily (low, medium and high doses). Renal and urinary disorders, and <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> with or without <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> were the most common underlying causes of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in children enrolled in this study. At the end of 2 weeks, valsartan reduced both systolic and diastolic blood pressure in a dose-dependent manner. Overall, the three dose levels of valsartan (low, medium and high) significantly reduced systolic blood pressure by -8, -10, -12 mm Hg from the baseline, respectively. Patients were re-randomized to either continue receiving the same dose of valsartan or were switched to placebo. In patients who continued to receive the medium and high doses of valsartan, systolic blood pressure at trough was -4 and -7 mm Hg lower than patients who received the placebo treatment. In patients receiving the low dose of valsartan, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose-dependent antihypertensive effect of valsartan was consistent across all the demographic subgroups. </p>
<p>In a clinical study involving 90 hypertensive pediatric patients 1 to 5 years of age with a similar study design, there was some evidence of effectiveness, but safety findings for which a relationship to treatment could not be excluded mitigate against recommending use in this age group. <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee </span><span class="Italics">Adverse Reactions</span><span class="Italics"> (6.1)</span><span class="Italics">]</span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2><span class="Bold">14.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></h2>
<p class="First">The Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial (Val-HeFT) was a multinational, double-blind study in which 5,010 patients with NYHA class II (62%) to IV (2%) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and LVEF &lt;40%, on baseline therapy chosen by their physicians, were randomized to placebo or valsartan (titrated from 40 mg twice daily to the highest tolerated dose or 160 mg twice daily) and followed for a mean of about 2 years. Although Val-HeFT’s primary goal was to examine the effect of valsartan when added to an ACE inhibitor, about 7% were not receiving an ACE inhibitor. Other background therapy included diuretics (86%), digoxin (67%), and beta-blockers (36%). The population studied was 80% male, 46% 65 years or older and 89% Caucasian. At the end of the trial, patients in the valsartan group had a blood pressure that was 4 mmHg systolic and 2 mmHg diastolic lower than the placebo group. There were two primary end points, both assessed as time to first event: all-cause mortality and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> morbidity, the latter defined as all-cause mortality, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> with resuscitation, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and the need for intravenous inotropic or vasodilatory drugs for at least 4 hours. These results are summarized in the table below.</p>
<a name="i5341f63d-bcf2-4d72-888f-38f1e6624c7f"></a><table>
<col width="124">
<col width="124">
<col width="124">
<col width="124">
<col width="124">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">Placebo</td>
<td class="Toprule" valign="bottom">Valsartan</td>
<td class="Toprule" valign="bottom">Hazard Ratio</td>
<td class="Toprule" valign="bottom">Nominal</td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">(N=2,499)</td>
<td valign="bottom">(N=2,511)</td>
<td valign="bottom">(95% CI*)</td>
<td valign="bottom">p-value</td>
</tr>
<tr>
<td class="Toprule" valign="bottom">All-cause mortality</td>
<td class="Toprule" valign="bottom">484</td>
<td class="Toprule" valign="bottom">495</td>
<td class="Toprule" valign="bottom">1.02</td>
<td class="Toprule" valign="bottom">0.8</td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">(19.4%)</td>
<td valign="bottom">(19.7%)</td>
<td valign="bottom">(0.90-1.15)</td>
<td valign="bottom"></td>
</tr>
<tr>
<td class="Toprule" valign="bottom">HF morbidity</td>
<td class="Toprule" valign="bottom">801</td>
<td class="Toprule" valign="bottom">723</td>
<td class="Toprule" valign="bottom">0.87</td>
<td class="Toprule" valign="bottom">0.009</td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">(32.1%)</td>
<td valign="bottom">(28.8%)</td>
<td valign="bottom">(0.79-0.97)</td>
<td valign="bottom"></td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5" valign="bottom">* CI = Confidence Interval</td></tr>
</tbody>
</table>
<p>Although the overall morbidity result favored valsartan, this result was largely driven by the 7% of patients not receiving an ACE inhibitor, as shown in the following table.</p>
<a name="if7bf0619-2b45-4239-80c0-152d6caf8132"></a><table>
<col width="159">
<col width="111">
<col width="119">
<col width="124">
<col width="124">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" colspan="2" valign="bottom">Without ACE Inhibitor</td>
<td class="Toprule" colspan="2" valign="bottom">With ACE Inhibitor</td>
</tr>
<tr>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">Placebo</td>
<td class="Toprule" valign="bottom">Valsartan</td>
<td class="Toprule" valign="bottom">Placebo</td>
<td class="Toprule" valign="bottom">Valsartan</td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">(N=181)</td>
<td valign="bottom">(N=185)</td>
<td valign="bottom">(N=2,318)</td>
<td valign="bottom">(N=2,326)</td>
</tr>
<tr>
<td class="Toprule" valign="bottom">Events (%)</td>
<td class="Toprule" valign="bottom">77 (42.5%)</td>
<td class="Toprule" valign="bottom">46 (24.9%)</td>
<td class="Toprule" valign="bottom">724 (31.2%)</td>
<td class="Toprule" valign="bottom">677 (29.1%)</td>
</tr>
<tr>
<td class="Toprule" valign="bottom">Hazard ratio (95% CI)</td>
<td class="Toprule" colspan="2" valign="bottom">0.51 (0.35, 0.73)</td>
<td class="Toprule" colspan="2" valign="bottom">0.92 (0.82, 1.02)</td>
</tr>
<tr class="Last">
<td class="Toprule" valign="bottom">p-value</td>
<td class="Toprule" colspan="2" valign="bottom">0.0002</td>
<td class="Toprule" colspan="2" valign="bottom">0.0965</td>
</tr>
</tbody>
</table>
<p>The modest favorable trend in the group receiving an ACE inhibitor was largely driven by the patients receiving less than the recommended dose of ACE inhibitor. Thus, there is little evidence of further clinical benefit when valsartan is added to an adequate dose of ACE inhibitor.</p>
<p>Secondary end points in the subgroup not receiving ACE inhibitors were as follows.</p>
<a name="ib9a5708d-86b9-4a31-83c0-d015554c0db1"></a><table>
<col width="257">
<col width="99">
<col width="108">
<col width="152">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule">Placebo</td>
<td class="Toprule">Valsartan</td>
<td class="Toprule">Hazard Ratio</td>
</tr>
<tr>
<td></td>
<td>(N=181)</td>
<td>(N=185)</td>
<td>(95% CI)</td>
</tr>
<tr>
<td class="Toprule">Components of HF morbidity</td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td class="Toprule">All-cause mortality</td>
<td class="Toprule">49 (27.1%)</td>
<td class="Toprule">32 (17.3%)</td>
<td class="Toprule">0.59 (0.37, 0.91)</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span> with resuscitation</td>
<td class="Toprule">2 (1.1%)</td>
<td class="Toprule">1 (0.5%)</td>
<td class="Toprule">0.47 (0.04, 5.20)</td>
</tr>
<tr>
<td class="Toprule">CHF therapy</td>
<td class="Toprule">1 (0.6%)</td>
<td class="Toprule">0 (0.0%)</td>
<td class="Toprule">–</td>
</tr>
<tr>
<td class="Toprule">CHF hospitalization</td>
<td class="Toprule">48 (26.5%)</td>
<td class="Toprule">24 (13.0%)</td>
<td class="Toprule">0.43 (0.27, 0.71)</td>
</tr>
<tr>
<td class="Toprule">Cardiovascular mortality</td>
<td class="Toprule">40 (22.1%)</td>
<td class="Toprule">29 (15.7%)</td>
<td class="Toprule">0.65 (0.40, 1.05)</td>
</tr>
<tr class="Last">
<td class="Toprule">Non-fatal morbidity</td>
<td class="Toprule">49 (27.1%)</td>
<td class="Toprule">24 (13.0%)</td>
<td class="Toprule">0.42 (0.26, 0.69)</td>
</tr>
</tbody>
</table>
<p>In patients not receiving an ACE inhibitor, valsartan-treated patients had an increase in <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and reduction in left ventricular internal diastolic diameter (LVIDD).</p>
<p>Effects were generally consistent across subgroups defined by age and gender for the population of patients not receiving an ACE inhibitor. The number of black patients was small and does not permit a meaningful assessment in this subset of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>
<span class="Bold">14.3</span><span class="Bold"> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span>
</h2>
<p class="First">The VALsartan In <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute myocardial iNfarcTion</span> trial (VALIANT) was a randomized, controlled, multinational, double-blind study in 14,703 patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and either <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (signs, symptoms or radiological evidence) or left ventricular systolic dysfunction (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤40% by radionuclide ventriculography or ≤35% by echocardiography or ventricular contrast angiography). Patients were randomized within 12 hours to 10 days after the onset of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> symptoms to one of three treatment groups: valsartan (titrated from 20 or 40 mg twice daily to the highest tolerated dose up to a maximum of 160 mg twice daily), the ACE inhibitor, captopril (titrated from 6.25 mg three times daily to the highest tolerated dose up to a maximum of 50 mg three times daily), or the combination of valsartan plus captopril. In the combination group, the dose of valsartan was titrated from 20 mg twice daily to the highest tolerated dose up to a maximum of 80 mg twice daily; the dose of captopril was the same as for monotherapy. The population studied was 69% male, 94% Caucasian, and 53% were 65 years of age or older. Baseline therapy included aspirin (91%), beta-blockers (70%), ACE inhibitors (40%), thrombolytics (35%) and statins (34%). The mean treatment duration was two years. The mean daily dose of Diovan in the monotherapy group was 217 mg. </p>
<p>The primary endpoint was time to all-cause mortality. Secondary endpoints included (1) time to cardiovascular (CV) mortality, and (2) time to the first event of cardiovascular mortality, reinfarction, or hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. The results are summarized in the table below:</p>
<a name="i92bea487-e494-4a00-8a04-b8cab4a96b19"></a><table>
<col width="119">
<col width="120">
<col width="77">
<col width="91">
<col width="108">
<col width="100">
<col width="73">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="3">Valsartan vs. Captopril<br>(N=4,909)      (N=4,909)</td>
<td class="Toprule" align="center" colspan="3">Valsartan + Captopril vs. Captopril<br>(N=4,885)           (N=4,909)</td>
</tr>
<tr>
<td></td>
<td class="Toprule">No. of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> <br>Valsartan/Captopril</td>
<td class="Toprule">Hazard Ratio<br>CI </td>
<td class="Toprule">p-value</td>
<td class="Toprule">No. of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span><br>Comb/Captopril</td>
<td class="Toprule">Hazard Ratio<br>CI </td>
<td class="Toprule">p-value</td>
</tr>
<tr>
<td class="Toprule">All-cause mortality<br>
</td>
<td class="Toprule">979 (19.9%)<br>/958 (19.5%)</td>
<td class="Toprule">1.001<br>(0.902, 1.111)<br>
</td>
<td class="Toprule">0.98</td>
<td class="Toprule">941 (19.3%)<br>/958 (19.5%)</td>
<td class="Toprule">0.984 <br>(0.886, 1.093)<br>
</td>
<td class="Toprule">0.73</td>
</tr>
<tr>
<td class="Toprule">CV mortality</td>
<td class="Toprule">827 (16.8%)<br>/830 (16.9%)</td>
<td class="Toprule">0.976<br>(0.875, 1.090)</td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr class="Last">
<td class="Toprule">CV mortality, hospitalization for HF, and recurrent non-fatal MI<br>
</td>
<td class="Toprule">
<br>1,529 (31.1%)<br>/1,567 (31.9%)</td>
<td class="Toprule">
<br>0.955<br>(0.881, 1.035)<br>
</td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
</tbody>
</table>
<p>There was no difference in overall mortality among the three treatment groups. There was thus no evidence that combining the ACE inhibitor captopril and the angiotensin II blocker valsartan was of value. </p>
<p>The data were assessed to see whether the effectiveness of valsartan could be demonstrated by showing in a non-inferiority analysis that it preserved a fraction of the effect of captopril, a drug with a demonstrated survival effect in this setting. A conservative estimate of the effect of captopril (based on a pooled analysis of 3 post-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> studies of captopril and 2 other ACE inhibitors) was a 14-16% reduction in mortality compared to placebo. Valsartan would be considered effective if it preserved a meaningful fraction of that effect and unequivocally preserved some of that effect. As shown in the table, the upper bound of the CI for the hazard ratio (valsartan/captopril) for overall or CV mortality is 1.09-1.11, a difference of about 9-11%, thus making it unlikely that valsartan has less than about half of the estimated effect of captopril and clearly demonstrating an effect of valsartan. The other secondary endpoints were consistent with this conclusion.</p>
<div class="Figure">
<img alt="Effects on Mortality Amongst Subgroups in VALIANT" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e4382de-df78-4821-b11e-c423442a7ff8&amp;name=diovan-tablets-02.jpg"><p class="MultiMediaCaption">Effects on Mortality Amongst Subgroups in VALIANT</p>
</div>
<p>There were no clear differences in all-cause mortality based on age, gender, race, or baseline therapies, as shown in the figure above. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold">  </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">Diovan (valsartan) is available as tablets containing valsartan 40 mg, 80 mg, 160 mg, or 320 mg. All strengths are packaged in bottles and unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages (10 strips of 10 tablets) as described below.</p>
<p>40 mg tablets are scored on one side and ovaloid with bevelled edges. 80 mg, 160 mg, and 320 mg tablets are unscored and almond-shaped with bevelled edges. </p>
<a name="idd3e8f84-ac35-4b5c-8210-dbad935b4031"></a><table>
<col width="89">
<col width="135">
<col width="72">
<col width="96">
<col width="72">
<col width="84">
<col width="96">
<col width="96">
<col width="0">
<col width="96">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="bottom">Tablet</td>
<td align="left" valign="bottom">Color</td>
<td align="center" colspan="2" valign="bottom">Deboss</td>
<td align="center" colspan="8" valign="bottom">NDC 0078-####-##</td>
</tr>
<tr>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom">Side 1</td>
<td class="Toprule" align="center" valign="bottom">Side 2</td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom">Bottle of</td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span></td>
</tr>
<tr>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">30</td>
<td class="Toprule" valign="bottom">90</td>
<td class="Toprule" valign="bottom">3500</td>
<td class="Toprule" valign="bottom">7000</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">14000</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">Packages of 100</td>
</tr>
<tr>
<td class="Toprule" valign="bottom">40 mg</td>
<td class="Toprule" valign="bottom">Yellow</td>
<td class="Toprule" align="center" valign="bottom">NVR</td>
<td class="Toprule" align="center" valign="bottom">DO</td>
<td class="Toprule" valign="bottom">0423-15</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">0423-06</td>
</tr>
<tr>
<td class="Toprule" valign="bottom">80 mg</td>
<td class="Toprule" valign="bottom"><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> red</td>
<td class="Toprule" align="center" valign="bottom">NVR</td>
<td class="Toprule" align="center" valign="bottom">DV</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">0358-34</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">0358-33</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">0358-06</td>
</tr>
<tr>
<td class="Toprule" valign="bottom">160 mg</td>
<td class="Toprule" valign="bottom">Grey-orange</td>
<td class="Toprule" align="center" valign="bottom">NVR</td>
<td class="Toprule" align="center" valign="bottom">DX</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">0359-34</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">0359-17</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" valign="bottom">0359-06</td>
</tr>
<tr class="Last">
<td class="Toprule" valign="bottom">320 mg</td>
<td class="Toprule" valign="bottom">Dark grey-violet</td>
<td class="Toprule" align="center" valign="bottom">NVR</td>
<td class="Toprule" align="center" valign="bottom">DXL</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" valign="bottom">0360-34</td>
<td class="Toprule" valign="bottom">0360-11</td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" valign="bottom">–</td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" valign="bottom">0360-06</td>
</tr>
</tbody>
</table>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59 - 86°F) [see USP Controlled Room Temperature].</p>
<p>Protect from moisture. </p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">17</span><span class="Bold">  </span><span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<span class="Bold">Information for Patients</span>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold Italics">Pregnancy:</span>  Female patients of childbearing age should be told that use of drugs like Diovan that act on the renin-angiotensin system during pregnancy can cause serious problems in the fetus and infant including: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>, poor development of skull bones, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Women using Diovan who become pregnant should notify their physician as soon as possible.</p>
<p>T2011-70</p>
<p><span class="Bold">DIOVAN (DYE’-o-van)</span></p>
<p><span class="Bold">(</span><span class="Bold">valsartan</span><span class="Bold">)</span><span class="Bold"> </span><span class="Bold">T</span><span class="Bold">ablets</span></p>
<p>Read the Patient Information that comes with DIOVAN before you take it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about DIOVAN, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about D</span><span class="Bold">IOVAN</span><span class="Bold">?</span></p>
<p><span class="Bold">Taking DIOVAN during pregnancy can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to your unborn baby. </span><span class="Bold">If you get pregnant, stop taking DIOVAN and call your doctor right away. </span><span class="Bold">Talk to your doctor about</span><span class="Bold"> other ways to lower your blood pressure if you plan to become pregnant.</span><span class="Bold"> </span></p>
<p><span class="Bold">What is DIOVAN?</span></p>
<p>DIOVAN is a prescription medicine called an angiotensin receptor blocker (ARB). It is used in adults to: </p>
<p>•
		     
	lower high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) in adults and children, 6 to 16 years of age.</p>
<p>•
		     
	treat <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in adults. In these patients, DIOVAN may lower the need for hospitalization that happens from <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
<p>•
		     
	improve the chance of living longer after a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) in adults.</p>
<p>DIOVAN is not for children under 6 years of age or children with certain kidney problems.</p>
<p><span class="Bold">High Blood Pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>).</span> Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. DIOVAN can help your blood vessels relax so your blood pressure is lower. </p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and vision problems. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span> occurs when the heart is weak and cannot pump enough blood to your lungs and the rest of your body. Just walking or moving can make you <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span>, so you may have to rest a lot. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart Attack</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>):</span> A <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> is caused by a blocked artery that results in damage to the heart muscle. </p>
<p><span class="Bold">What should I tell my doctor before taking DIOVAN?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions including whether you:</span></p>
<p>•
		     
	have any allergies. See the end of this leaflet for a complete list of ingredients in DIOVAN.</p>
<p>•
		     
	have a heart condition</p>
<p>•
		     
	have liver problems</p>
<p>•
		     
	have kidney problems</p>
<p>•
		     
	<span class="Bold">are pregnant or planning to become pregnant.</span> See “What is the most important information I should know about DIOVAN??</p>
<p>•
		     
	are breast-feeding. It is not known if DIOVAN passes into your breast milk. You and your doctor should decide if you will take DIOVAN or breast-feed, but not both. Talk with your doctor about the best way to feed your baby if you take DIOVAN.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take</span> including prescription and nonprescription medicines, vitamins and herbal supplements. Especially tell your doctor if you take:</p>
<p>•
		     
	other medicines for high blood pressure or a heart problem</p>
<p>•
		     
	water pills (also called “diuretics?)</p>
<p>•
		     
	potassium supplements</p>
<p>•
		     
	a salt substitute</p>
<p>•
		     
	nonsteroidal anti-inflammatory drugs (like ibuprofen or naproxen)</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your doctor and pharmacist when a new medicine is prescribed. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.</p>
<p><span class="Bold">How should I take DIOVAN?</span></p>
<p>•
		     
	Take DIOVAN exactly as prescribed by your doctor. </p>
<p>•
		     
	For treatment of high blood pressure, take DIOVAN one time each day, at the same time each day.</p>
<p>•
		     
	If your child cannot swallow tablets, or if tablets are not available in the prescribed strength, your pharmacist will mix DIOVAN as a liquid suspension for your child. If your child switches between taking the tablet and the suspension, your doctor will adjust the dose as needed. Shake the bottle of suspension well for at least 10 seconds before pouring the dose of medicine to give to your child.</p>
<p>•
		     
	For adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or who have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, take DIOVAN two times each day, at the same time each day. Your doctor may start you on a low dose of DIOVAN and may increase the dose during your treatment. </p>
<p>•
		     
	DIOVAN can be taken with or without food.</p>
<p>•
		     
	If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the next dose at your regular time.</p>
<p>•
		     
	If you take too much DIOVAN, call your doctor or Poison Control Center, or go to the nearest hospital emergency room.</p>
<p><span class="Bold">What are the possible side effects of DIOVAN?</span></p>
<p><span class="Bold">DIOVAN may cause the following serious side effects:</span></p>
<p><span class="Bold">Injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby</span><span class="Bold">. </span>See “What is the most important information I should know about DIOVAN??</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low Blood Pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>)</span><span class="Bold">. </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you also take water pills, are on a low-salt diet, get dialysis treatments, have heart problems, or get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Lie down, if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. Call your doctor right away.</p>
<p><span class="Bold">Kidney problems. </span>Kidney problems may get worse in people that already have kidney disease. Some people will have changes on blood tests for kidney function and may need a lower dose of DIOVAN. Call your doctor if you get <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands, or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your doctor should check your kidney function before prescribing DIOVAN. </p>
<p><span class="Bold">The most common side effects of DIOVAN used to treat people with high blood pressure include:</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu symptoms</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></p>
<p>•
		     
	stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p>Side effects were generally mild and brief. They generally have not caused patients to stop taking DIOVAN. </p>
<p><span class="Bold">The most common side effects of DIOVAN used to treat people with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> include:</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p>•
		     
	joint and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></p>
<p>•
		     
	high <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span></p>
<p><span class="Bold">Common side effects of DIOVAN used to treat people after a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> which caused them to stop taking the drug include:</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></p>
<p>•
		     
	high blood creatinine (decreased kidney function)</p>
<p>•
		     
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p>Tell your doctor if you get any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of DIOVAN. For a complete list, ask your doctor or pharmacist.</p>
<p><span class="Bold">How do I store DIOVAN?</span></p>
<p>•
		     
	Store DIOVAN tablets at room temperature between 59o to 86oF (15ºC - 30ºC).</p>
<p>•
		     
	Keep DIOVAN tablets in a closed container in a dry place.</p>
<p>•
		     
	Store bottles of DIOVAN suspension at room temperature less than 86ºF (30ºC) for up to 30 days, or refrigerate between 35ºF - 46ºF (2ºC - 8ºC) for up to 75 days.</p>
<p>•
		     
	Keep DIOVAN and all medicines out of the reach of children.</p>
<p><span class="Bold">General information about DIOVAN</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use DIOVAN for a condition for which it was not prescribed. Do not give DIOVAN to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about DIOVAN. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about DIOVAN that is written for health professionals.</p>
<p>For more information about DIOVAN, ask your pharmacist or doctor, visit <span class="Underline">www.DIOVAN.com</span> on the Internet, or call <span class="Bold">1-866-404-6361</span>.</p>
<p><span class="Bold">What are the ingredients in DIOVAN?</span></p>
<p>Active ingredient:  valsartan </p>
<p>Inactive ingredients:  colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides (yellow, black and/or red), magnesium stearate, microcrystalline cellulose, polyethylene glycol 8000, and titanium dioxide </p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corp.</p>
<p>East Hanover, NJ 07936</p>
<p>© Novartis</p>
<p>T2011-70/T2011-71</p>
<p>April 2011/April 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">160 mg</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0359-34</p>
<p>Diovan® </p>
<p>valsartan </p>
<p>160 mg</p>
<p>90 Tablets</p>
<br><p><img alt="55289817 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e4382de-df78-4821-b11e-c423442a7ff8&amp;name=55289817.jpg"></p>
<p>PDRx Label<br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIOVAN
                         		
					</strong><br><span class="contentTableReg">valsartan tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-817(NDC:0078-0359)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">160 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GRAY, ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (almond-shaped with bevelled edges) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;DX</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-817-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021283</td>
<td class="formItem">07/01/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cf438b80-ad50-4c52-b53a-7cff58f1b2e0</div>
<div>Set id: 8e4382de-df78-4821-b11e-c423442a7ff8</div>
<div>Version: 7</div>
<div>Effective Time: 20110401</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
